Skip to main content
Top
Published in: International Journal of Hematology 4/2010

01-11-2010 | Original Article

Establishment of an HS23 stromal cell-dependent myeloma cell line: fibronectin and IL-6 are critical

Authors: Akira Sakai, Miyo Oda, Mitsuhiro Itagaki, Noriaki Yoshida, Koji Arihiro, Akiro Kimura

Published in: International Journal of Hematology | Issue 4/2010

Login to get access

Abstract

A multiple myeloma (MM) cell line, MSG1, which depends on HS23 stromal cells for its survival, was established from the pleural effusion of a patient with MM who expressed the M-protein of IgA-λ in his serum. During the first 2 months of culture, the myeloma cells survived on adhesive cells from the pleural effusion and, subsequently, they continued to proliferate on HS23 stromal cells. The phenotype of the established MSG1 cell line was: CD138+, CD38++, CD19, CD56, VLA-4+, VEGFR1+ and VEGFR2+. Immunohistochemical staining also demonstrated expression of the IgA and λ chain in MSG1 cytoplasm. Karyotype analysis indicated complex chromosomal abnormalities; hypertriploidy, including the deletion of chromosomes 13 and 17, and c-myc translocation. MSG1 cells continued to proliferate, not only when co-cultured with HS23 cells, but also when cultured only on fibronectin-coated plates with the supernatant of HS23 cells or with control medium containing IL-6. Tocilizumab, an anti-IL-6 receptor antibody, inhibited MSG1 survival under these conditions. Therefore, MSG1 may be a unique myeloma cell line that is useful for the study of cell adhesion-mediated drug resistance induced by adhesion molecules and IL-6 stimulation of myeloma cells.
Literature
1.
go back to reference Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Can. 2007;7:585–97.CrossRef Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Can. 2007;7:585–97.CrossRef
2.
go back to reference Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93:1658–67.PubMed Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93:1658–67.PubMed
3.
go back to reference Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004;104:2484–91.CrossRefPubMed Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004;104:2484–91.CrossRefPubMed
4.
go back to reference Sakai A, Marti GE, Caporaso N, Pittaluga S, Touchman JW, Fend F, et al. Analysis of expressed immunoglobulin heavy chain genes in familial B-CLL. Blood. 2000;95:1413–9.PubMed Sakai A, Marti GE, Caporaso N, Pittaluga S, Touchman JW, Fend F, et al. Analysis of expressed immunoglobulin heavy chain genes in familial B-CLL. Blood. 2000;95:1413–9.PubMed
5.
go back to reference Roecklein BA, Torok-Storb B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood. 1995;85:997–1005.PubMed Roecklein BA, Torok-Storb B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood. 1995;85:997–1005.PubMed
6.
go back to reference Maniatis T, Fritsch E, Sambrook I. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory. 1987. Maniatis T, Fritsch E, Sambrook I. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory. 1987.
7.
go back to reference Shibata D, Weiss LM, Nathwani BN, Brynes RK, Levine AM. Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin’s lymphoma. Blood. 1991;77:1527–33.PubMed Shibata D, Weiss LM, Nathwani BN, Brynes RK, Levine AM. Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin’s lymphoma. Blood. 1991;77:1527–33.PubMed
8.
go back to reference Monini P, Lellis LD, Fabris M, Rigolin F, Cassai E. Kaposi’s sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen. New Eng J Med. 1996;334:1168–72.CrossRefPubMed Monini P, Lellis LD, Fabris M, Rigolin F, Cassai E. Kaposi’s sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen. New Eng J Med. 1996;334:1168–72.CrossRefPubMed
9.
go back to reference Kawano MM, Hunag N, Harada H, Harada Y, Sakai A, Tanaka H, et al. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood. 1993;82:564–70.PubMed Kawano MM, Hunag N, Harada H, Harada Y, Sakai A, Tanaka H, et al. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood. 1993;82:564–70.PubMed
10.
go back to reference Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3–21.PubMed Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3–21.PubMed
11.
go back to reference Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98:428–35.CrossRefPubMed Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98:428–35.CrossRefPubMed
12.
go back to reference Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332:83–5.CrossRefPubMed Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332:83–5.CrossRefPubMed
13.
go back to reference Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica. 2000;85:800–5.PubMed Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica. 2000;85:800–5.PubMed
14.
go back to reference Dankbar B, Padro T, Leo R, Feldmann B, Kropff K, Mesters RM, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95:2630–6.PubMed Dankbar B, Padro T, Leo R, Feldmann B, Kropff K, Mesters RM, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95:2630–6.PubMed
15.
go back to reference Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE, et al. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene. 2010;29:1190–202.CrossRefPubMed Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE, et al. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene. 2010;29:1190–202.CrossRefPubMed
16.
go back to reference Yoshino-Hoshino N, Adachi Y, Aoki C, Pereboev A, Curiel DT, Nishimoto N. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res. 2007;67:871–975.CrossRef Yoshino-Hoshino N, Adachi Y, Aoki C, Pereboev A, Curiel DT, Nishimoto N. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res. 2007;67:871–975.CrossRef
17.
go back to reference Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, et al. Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene. 2009;28:231–42.CrossRefPubMed Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, et al. Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene. 2009;28:231–42.CrossRefPubMed
18.
go back to reference Matsuo Y, Drexler HG, Nishizaki C, Harashima A, Fukuda S, Kozuka T, et al. Human bone marrow stroma-dependent cell line MOLP-5 derived from a patient in leukaemic phase of multiple myeloma. Br J Haemat. 2000;109:54–63.CrossRef Matsuo Y, Drexler HG, Nishizaki C, Harashima A, Fukuda S, Kozuka T, et al. Human bone marrow stroma-dependent cell line MOLP-5 derived from a patient in leukaemic phase of multiple myeloma. Br J Haemat. 2000;109:54–63.CrossRef
Metadata
Title
Establishment of an HS23 stromal cell-dependent myeloma cell line: fibronectin and IL-6 are critical
Authors
Akira Sakai
Miyo Oda
Mitsuhiro Itagaki
Noriaki Yoshida
Koji Arihiro
Akiro Kimura
Publication date
01-11-2010
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2010
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0698-2

Other articles of this Issue 4/2010

International Journal of Hematology 4/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine